Chernett Jorey purchased $104K of XGN

Chernett Jorey purchased 14,000 shares of EXAGEN INC. (XGN) at $7.46 ($0.10M total) on 2026-10-19.

Original reporting
SEC EDGAR · Chernett Jorey
Published Oct 20, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$XGN
Neutral
medium confidence
Mentioned
$XGN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XGNNeutralLow
01

Why it matters

The disclosed purchase adds a modest data point for analysts tracking insider sentiment but is unlikely to move the stock significantly.

02

Market read

The filing provides fresh insider activity data but limited trading relevance due to small transaction size.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: pre-market today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$XGNNeutralMedium confidence
Context

Form 4 shows insider Chernett Jorey bought 14,000 shares for $104,440, increasing holdings to 2.6M shares.

Expected impact

likely slight upward pressure as market prices in insider confidence

Evidence & confidence

Purchase size is modest relative to float; insider is a 10% owner, so incremental buying is not a strong catalyst.

Market effects

Minimal effect on biotech sector; insider activity is routine for a 10% owner.

No regional impact; confined to US-listed biotech investors.

Negligible global relevance.

Counterpoint

The purchase could be a routine portfolio adjustment rather than a bullish signal.

Key entities

  • Exagen Inc.

    US-listed biotech company (NASDAQ: XGN) whose insider made a purchase.

  • Chernett Jorey

    Insider and 10% owner of Exagen Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XGNLow

Exagen Inc. Reports Third Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio

$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

$XGNMed

Exagen Inc. Reports Second Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,